(Total Views: 346)
Posted On: 07/05/2021 2:41:10 PM
Post# of 22465
Squires stated at trial in Nov 2020 that QMCH was bundled (aka deployed).
Other than what is stated in the Pasaca agreement, I don't think QMC has been paid what it's owed yet and therefore has been conservative by not reporting what is not received yet, a figure that may be increasing as time goes by.
There are probably laws against reporting income "unofficially" as a non-reporting company, IDK.
Innova has not publicly reported either, to my knowledge. Why not? Possible mutual NDA to report revenue together at some milestone? IDK.
Possible revenue streams include QMCH, anticounterfeiting and Gold NP or QD for use in tests, and an AI component (?) at rates of over x millions per day.
We all know that Squires decided to go with the license and royalties sales method, which he stated in a shareholders letter. Not coincidentally, that's also similar to how DLT is "sold". There is a POC, or Proof of Concept, and when approved, there is implementation and deployment. There are multiple payment schemes that could be chosen for a DLT, it's DAPP and ongoing services which could include a combination of lump sum, size of DLT and ongoing use.
That's why I think revenue is accumulating but has not been paid
I also think continuing deployment could be continuing to translate the software into other languages, modify it for private label use by companies, or adapt it to other uses such as clinical trials. IDK.
Other than what is stated in the Pasaca agreement, I don't think QMC has been paid what it's owed yet and therefore has been conservative by not reporting what is not received yet, a figure that may be increasing as time goes by.
There are probably laws against reporting income "unofficially" as a non-reporting company, IDK.
Innova has not publicly reported either, to my knowledge. Why not? Possible mutual NDA to report revenue together at some milestone? IDK.
Possible revenue streams include QMCH, anticounterfeiting and Gold NP or QD for use in tests, and an AI component (?) at rates of over x millions per day.
We all know that Squires decided to go with the license and royalties sales method, which he stated in a shareholders letter. Not coincidentally, that's also similar to how DLT is "sold". There is a POC, or Proof of Concept, and when approved, there is implementation and deployment. There are multiple payment schemes that could be chosen for a DLT, it's DAPP and ongoing services which could include a combination of lump sum, size of DLT and ongoing use.
That's why I think revenue is accumulating but has not been paid
I also think continuing deployment could be continuing to translate the software into other languages, modify it for private label use by companies, or adapt it to other uses such as clinical trials. IDK.
(0)
(0)
